Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Laekna, Inc. Share Price

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 04:59:36 16/05/2024 BST 		5-day change 1st Jan Change
7.47 HKD -4.23% Intraday chart for Laekna, Inc. +11.92% -63.67%
05-10 Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug MT
05-10 Lekna, Inc. Obtains IND Approval from the CDE for LAE102 CI

Financials

Sales 2021 111K 15.39K 120K 1.21M Sales 2022 280K 38.81K 303K 3.06M Capitalization 2.81B 389M 3.04B 30.69B
Net income 2021 -749M -104M -810M -8.18B Net income 2022 -782M -108M -846M -8.54B EV / Sales 2021 * -
Net cash position 2021 * - 0 0 0 Net cash position 2022 * - 0 0 0 EV / Sales 2022 * -
P/E ratio 2021 *
-
P/E ratio 2022 *
-
Employees 89
Yield 2021 *
-
Yield 2022 *
-
Free-Float 8.78%
More Fundamentals * Assessed data

Chart Laekna, Inc.

Dynamic Chart

Latest news about Laekna, Inc.

Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102 CI
Laekna Scores FDA Nod for Obesity Drug LAE102 MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102 CI
Laekna Shrinks Loss in Fiscal 2023 MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102 CI
Laekna, Inc. Announces Management Changes CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34% MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China CI
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer CI
Laekna, Inc. Announces Executive Changes CI
More news

Press releases Laekna, Inc.

Laekna Releases 2023 ESG Report PR
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 PR
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results PR
Laekna, Inc. (2105.HK) Announces Interim Results 2023 PR
More press releases

Quotes and Performance

1 day-7.31%
1 week+11.92%
Current month+16.99%
1 month+10.89%
3 months+75.49%
6 months-66.37%
Current year-63.67%
More quotes

Highs and lows

1 week
6.45
Extreme 6.45
8.08
1 month
5.02
Extreme 5.02
8.08
Current year
3.15
Extreme 3.15
19.76
1 year
3.15
Extreme 3.15
26.45
3 years
3.15
Extreme 3.15
26.45
5 years
3.15
Extreme 3.15
26.45
10 years
3.15
Extreme 3.15
26.45
More quotes

Company Profile

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LAEKNA, INC. Stock Laekna, Inc.
-63.67% 389M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 106B
BIONTECH SE Stock BioNTech SE
-12.64% 22.24B
ARGENX SE Stock argenx SE
+0.44% 21.25B
GENMAB A/S Stock Genmab A/S
-4.18% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-23.95% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2105 Stock